Effect of Rosiglitazone Maleate on inflammation following cerebral ischemia/reperfusion in rats

Abstract

In order to evaluate the neuroprotective effect of Rosiglitazone Maleate (RSG) against brain ischemic injury, the effects of Rosiglitazone Maleate on the inflammation following cerebral ischemia/reperfusion were investigated. Focal cerebral ischemia was induced by the intraluminal thread for cerebral middle artery (MCA) occlusion. Rosiglitazone Maleate at concentrations of 0.5, 2 and 5 mg/kg was infused by intragastric gavage twice immediately and 2 h after MCA occlusion, respectively. The effects of Rosiglitazone Maleate on brain swelling, myeloperoxidase and interleukin-6 mRNA level in brain tissue after MCA occlusion and reperfusion were evaluated. The results showed that as compared with the model control group, RSG (0.5 mg/kg) had no significant influence on brain swelling (P>0.05), but 2 mg/kg and 5 mg/kg RSG could significantly alleviate brain swelling (P<0.05). All different doses of RSG could obviously reduce MPO activity in brain tissue after MCA occlusion and reperfusion in a dose-dependent manner. RSG (0.5 and 2 mg/kg) could decrease the expression levels of IL-6 mRNA in brain tissue after MCA occlusion and reperfusion to varying degrees (P<0.05) with the difference being significant between them. It was concluded that RSG could effectively ameliorate brain ischemic injury after 24 h MCA occlusion and inhibit the inflammatory response after ischemia-reperfusion in this model.

Keywords

Rosiglitazone Maleate / rat / brain ischemia / myeloperoxidase / interleukin-6

References

[1] CampbellI. W.. The clinical significance of PPAR gamma agonism. Curr Mol Med, 2005, 5(3): 349-363

[2] ItoK., ShimadaJ., KatoD., et al.. Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on lung ischemia-reperfusion injury in rats. Eur J Cadiothorac Surg, 2004, 25(4): 530-536

[3] ItoH., NakanoA., KinoshitaM., et al.. Pioglitazone, a peroxisome oxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injuy in a rat model. Lab Invest, 2003, 83(12): 1715-1721

[4] AbdelrahmanM., SivarajahA., ThiemermannC.. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res, 2005, 65(4): 772-781

[5] BeckerK. J.. Inflammation and acute stroke. Curr Opin Neurol, 1998, 11(1): 45-49

[6] RitrerL., CoullB., DavisgomanG., et al.. Leukocytes accumulate in the cerebral microcirculation during the first hour of reperfusion following stroke. FASEB J, 1998, 12: 188-196

[7] IalentiA., GrassiaG., Di MeglioP., et al.. Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway. Mol Pharmacol, 2005, 67(5): 1620-1628

[8] ArtwohlM., HolzenbeinT., FurnsinnC., et al.. Thiazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells. Thromb Haemost, 2005, 93(5): 810-815

[9] PistroschF., HerbrigK., OelschlaegelU., et al.. PPAR gamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis, 2005, 183(1): 163-167

[10] GameB. A., MaldonadoA., HeL., et al.. Pioglitazone inhibits MMP-1 expression in vascular smooth muscle cells through a mitogen-activated protein kinase-independent mechanism. Atherosclerosis, 2005, 178(2): 249-256